| 崔容海,张 琪,刘洢凡,陈泽莲,王 晨.密固达与地舒单抗治疗原发性骨质疏松的成本-效用分析[J].现代生物医学进展英文版,2023,(15):2941-2946. |
| 密固达与地舒单抗治疗原发性骨质疏松的成本-效用分析 |
| Cost-effectiveness Analysis of Miguda and Desumab in the Treatment of Primary Osteoporosis |
| Received:February 06, 2023 Revised:February 28, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.15.027 |
| 中文关键词: 密固达 地舒单抗 原发性骨质疏松 成本-效用分析 |
| 英文关键词: Miguta Desuchumab Primary osteoporosis Cost-effectiveness analysis |
| 基金项目:四川省乐山市科技计划项目（21SZD120） |
|
| Hits: 649 |
| Download times: 444 |
| 中文摘要: |
| 摘要 目的：评价密固达与地舒单抗治疗原发性骨质疏松的经济性。方法：基于我国卫生体系角度，采用Excel2010软件构建Markov评估模型，利用成本-效用分析的方法评估密固达与地舒单抗治疗原发性骨质疏松的经济性。成本、健康效用值及药物治疗源自已发表的文献。模型循环周期为1年，时效为终生。采用单因素敏感性分析和概率分析评估模型参数变化对结果的影响。结果：地舒单抗用药方案比密固达方案给患者带来0.76质量调整生命年（QALYs）但同时用药成本也高于密固达方案2101.31元，其ICER为2764.88元/QALY。单因素敏感性分析发现药物成本对结果影响较大。概率敏感性分析结果显示，当采用3倍我国2022年人均国内生产总值（GDP）作为意愿支付阈值时，地舒单抗方案更具有经济性。结论：低于3倍我国2022年GDP阈值条件下，地舒单抗治疗原发性骨质疏松更具有经济性。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the economy of Miguda and Desumab in the treatment of primary osteoporosis. Methods: Based on the perspective of China's health system, a Markov evaluation model was built using Excel 2010 software, and the cost-effectiveness analysis method was used to evaluate the economics of Miguta and Desumab in the treatment of primary osteoporosis. Cost, health utility value and drug treatment are derived from published literature. The cycle of the model is 1 year and the time limit is lifetime. Single factor sensitivity analysis and probability analysis were used to evaluate the impact of model parameter changes on the results. Results: Compared with Miguda regimen, desumab regimen brought 0.76 quality-adjusted life years (QALYs) to patients, but the cost of medication was also higher than Miguda regimen at 2101.31 yuan, and its ICER was 2764.88 yuan/QALY. The single-factor sensitivity analysis found that the drug cost had a great impact on the results. The result of probability sensitivity analysis shows that when three times of China's gross domestic product (GDP) per capita in 2022 is used as the threshold of willingness to pay, the desuzumab scheme is more economical. Conclusion: Desumab is more economical in the treatment of primary osteoporosis under the condition that it is less than 3 times of China's 2022 GDP threshold. |
|
View Full Text
View/Add Comment Download reader |
| Close |
